Page 1

company announcement Financial report for the period 1 January 2021 to 30 June 2021 4 August 2021 ● Novo Nordisk's net profit increased by 10 % in the first six months of 2021 Operating profit decreased by 1 % in Danish kroner and increased by 9 % at constant exchange rates ( CER ) . Sales increased by 5 % in Danish kroner and by 12 % at CER to DKK 66.8 billion . Sales in International Operations increased by 7 % in Danish kroner ( 13 % at CER ) , and sales in North America Operations increased by 1 % in Danish kroner ( 11 % at CER ) . . Sales within Diabetes and Obesity care increased by 5 % in Danish kroner to DKK 56.9 billion ( 13 % at CER ) , driven by GLP - 1 growth of 21 % in Danish kroner ( 30 % at CER ) reflecting the uptake of Ozempic® and Rybelsus® . Obesity care grew by 23 % in Danish kroner ( 34 % at CER ) and Biopharm sales remained unchanged in Danish kroner ( increased by 7 % at CER ) . In June 2021 , Wegovy ™ , semaglutide 2.4 mg , was made available to patients in the US following the approval from the US Food and Drug Administration ( FDA ) for weight management in adults living with obesity . PROFIT AND LOSS For the 2021 outlook , sales growth is now expected to be 10-13 % at CER ( previously 6-10 % ) , and operating profit growth is now expected to be 9-12 % at CER ( previously 5-9 % ) . Sales growth reported in Danish kroner is still expected to be 4 percentage points lower than at CER and operating profit growth reported in Danish kroner is now expected to be 5 percentage points lower than at CER . DKK million Net sales Operating profit Net profit Diluted earnings per share ( in DKK ) * CER : Constant exchange rates ( average 2020 ) . H1 2021 Novo Nordisk A / S Investor Relations 66,845 29,761 Novo Allé 2880 Bagsværd Denmark 24,746 10.71 H1 2020 63,881 30,140 22,522 9.58 BC Growth as reported novo nordisk 5 % ( 1 % ) 10 % 12 % Telephone : +45 4444 8888 www.novonordisk.com Growth at CER * Lars Fruergaard Jørgensen , president and CEO : " We are pleased with the sales growth in the first half of 2021. The growth is driven by all geographical areas within International Operations as well as North America Operations , and by all therapy areas , in particular by our portfolio of GLP - 1 treatments . Within R & D , we reached a very important milestone with the approval of Wegovy ™ in the US , offering people living with obesity a new , efficacious treatment option . The strong financial performance in the first half of 2021 and the initial substantial demand for Wegovy ™ in the US have enabled us to raise our outlook for the full year . " 12 % 9 % On 4 August 2021 at 19.00 CEST , corresponding to 13.00 PM EDT , an earnings call will be held . Investors will be able to listen in via a link on novonordisk.com , which can be found under ' Investors ' . N / A N / A CVR Number : 24 25 67 90 Company announcement No 48 / 2021